Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive intra-arterial urokinase after successful thrombectomy for anterior-circulation large-vessel occlusion stroke
ChiCTR2200065617Phase 3Completed
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Nov 2022
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of urokinase in ischemic stroke (2 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoint: Proportion of patients with mRS score 0 to 1 at 90 days. Started Nov 2022; status: completed.
02
Drugs
urokinase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2200065617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065617.